Features
Suprachoroidal Drug Delivery Technology
The first FDA approval ushers in a new clinical reality.
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
Flow Mechanics of Suprachoroidal Injection
A compartmentalized delivery route facilitates more targeted retinal drug delivery.
By VENKATKRISH M. KASETTY, MD, Luke G. Qin, Diego Espinosa-Heidmann, MD, et al.
Suprachoroidal Delivery as a Novel Avenue for Retinal Gene Therapy
Clinical trials are investigating suprachoroidal gene therapy for wet AMD and DR.
By Arshad M. Khanani, MD, MA, FASRS, Hannah Khan, MPH, Tyler M. Ewing, MS
Light-activated Suprachoroidal Therapy for the First-line Treatment of Indeterminate Lesions and Small Choroidal Melanoma
This novel approach could be applied to various ocular oncology indications.
By Buse Guneri Beser, MD, FEBO, FICO, Hakan Demirci, MD
New Developments in Suprachoroidal and Subretinal Drug Delivery Technology
Trials in humans are progressing.
By David Xu, MD, M. Ali Khan, MD, Allen C. Ho, MD
Suprachoroidal Drug Delivery in the Treatment of Noninfectious Uveitis
Recent clinical trials have demonstrated promising results.
By Steven Yeh, MD, Tolulope Fashina, MD, MPH
Web Exclusives
Nonsurgical Management of Vision Degrading Myodesopsia
Part 3 of a 3-part series on a vitreous pathology that can profoundly impact patients' lives.
By Wei Gui, MD, Ronald H. Silverman, PhD, J. Sebag, MD
Departments
SPONSOR WELCOME LETTER: What Is the Real Potential of the Suprachoroidal Space?
The future has arrived, and this is just the beginning.
By Joseph Ponzo
GUEST EDITORIAL: An Inflection Point for Retinal Therapy
Suprachoroidal administration could change the landscape of retina.
By Mark R. Barakat, MD
UPFRONT: A Journey to the Suprachoroidal Space
By Peter K. Kaiser, MD
UVEITIS CORNER: Current Management of Pediatric Uveitis
Consider these guidelines when facing these challenging patient encounters.
By Sruthi Arepalli, MD
NEW PRODUCT APPLICATIONS: The Next Generation of Vitrectomy Lighting
Transilluminating depressor offers brighter visualization.
By Karen Appold, contributing writer
News
SUBSPECIALTY NEWS: Data presented on THR-149 and THR-687 for DME, pegcetacoplan NDA submitted, AREDS2 benefit confirmed, and more.
By Rochelle Nataloni, contributing writer